Indian Journal of Cancer Home 

ORIGINAL ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2007  |  Volume : 44  |  Issue : 2  |  Page : 56--61

Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer

Ezzeldin M Ibrahim1, Ahmed A Zeeneldin1, Aboelkhair M Al-Gahmi1, Yasser A Sallam1, Ehab E Fawzi2, Yasser A Bahadur2 
1 Department of Oncology and Hematology, Sections of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
2 Department of Oncology and Hematology, Sections of Radiation Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia

Correspondence Address:
Ezzeldin M Ibrahim
Department of Oncology and Hematology, Sections of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah
Saudi Arabia

Background: Cetuximab-based combination chemotherapy (CBCC) proved safe and effective as second-line strategy for metastatic colorectal cancer (mCRC). This prospective phase-II study was designed to assess the efficacy and safety of CBCC as first-, second- or third-line among Saudi patients with mCRC. Materials and Methods: Patients with mCRC were offered CBCC to assess time-to-disease progression (TTP), response rate and duration, overall survival (OS) and safety. Results: Nineteen patients were eligible and their median age was 51 years. Seven patients received CBCC as first-line and 12 as second- or third-line. Responses: 11 (58%) partial responses, 5 (26%) stable disease and 3 (16%) disease progressions. The median response duration was 4.3 months [95% confidence interval (CI): 3.4-5.2 months]. The median TTP was 6.8 months (95% CI: 2-13.9 months) for all 19 patients compared to 9.3 months (95% CI: 3.9-14.6 months) for the seven patients who received CBCC as first-line. The median OS for the entire population was 12.3 months (95% CI could not be determined). On the other hand, while the median OS for those who received CBCC as first-line have not been reached, the median OS for those who received CBCC after failure of other salvage therapies was 12.3 months (95% CI: 3.2-21.4 months). CBCC was generally tolerable. One patient had a severe hypersensitivity reaction and another fatal cardiac arrest. Conclusion: CBCC is active with an acceptable safety profile. Until results from phase-III clinical trials are available, using CBCC as first-line is probably justified.


How to cite this article:
Ibrahim EM, Zeeneldin AA, Al-Gahmi AM, Sallam YA, Fawzi EE, Bahadur YA. Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer.Indian J Cancer 2007;44:56-61


How to cite this URL:
Ibrahim EM, Zeeneldin AA, Al-Gahmi AM, Sallam YA, Fawzi EE, Bahadur YA. Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer. Indian J Cancer [serial online] 2007 [cited 2020 Nov 27 ];44:56-61
Available from: https://www.indianjcancer.com/article.asp?issn=0019-509X;year=2007;volume=44;issue=2;spage=56;epage=61;aulast=Ibrahim;type=0